Basic Information
| RNALocate ID: | RLID:01001794 |
| RNA Symbol: | hsa-miR-152-3p |
| Localization: | Mitochondrion |
RNA Information
| RNA Name: | hsa-miR-152 |
| RNA ID: | miRBase:MIMAT0000438 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 21637849 |
| Tissue/Cell Line: | Skeletal muscle myoblasts |
| Method: | ISH|qRT-PCR |
| Description: | List of microRNA significantly detected in the mitochondrial mRNA at three increasing mtRNA inputs (1, 5 and 35 uL). Table S3 List of microRNA significantly detected (Cp<35) in the mitochondrial mRNA at the two highest mtRNA inputs (5 and 35 uL). Data are collected from Table 4 and S3. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001792 | Cytoplasm | Neural progenitor cells | 21363885 |
| RLID:01001793 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001795 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001796 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11001822 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11001823 | Exosome | Ovarian follicular fluid | 22116803 |
| RLID:11001824 | Exosome | Breast milk | 22211110 |
| RLID:11001825 | Exosome | Brain tissue | 23382797 |
| RLID:11001826 | Exosome | Plasma | 23663360 |
| RLID:11001827 | Extracellular vesicle | HEK-293T cells | 22849433 |
| RLID:11001828 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000087 | Exosome | Breast milk|Tongue tissue | |
| RLID-D:11000366 | Microvesicle | Blood|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-152-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-17001 |
| MNDR | hsa-miR-152-3p | Oral squamous cell carcinoma | MNDR-E-MI-17002 |
| MNDR | hsa-miR-152-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-17003 |
| MNDR | hsa-miR-152-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-17004 |
| MNDR | hsa-miR-152-3p | Lymphoma | MNDR-E-MI-17005 |
| MNDR | hsa-miR-152-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-17006 |
| MNDR | hsa-miR-152-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-17007 |
| MNDR | hsa-miR-152-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-17008 |
| MNDR | hsa-miR-152-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-17009 |
| MNDR | hsa-miR-152-3p | Her2-receptor positive breast cancer | MNDR-E-MI-17010 |
| MNDR | hsa-miR-152-3p | Niemann-pick disease type c | MNDR-E-MI-17011 |
| MNDR | hsa-miR-152-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-17012 |
| MNDR | hsa-miR-152-3p | Prostate cancer | MNDR-E-MI-17013 |
| MNDR | hsa-miR-152-3p | Gastric cancer | MNDR-E-MI-17014 |
| MNDR | hsa-miR-152-3p | Alzheimer disease | MNDR-E-MI-17015 |
| MNDR | hsa-miR-152-3p | Bladder cancer | MNDR-E-MI-17016 |
| MNDR | hsa-miR-152-3p | Dysautonomia familial | MNDR-E-MI-17017 |
| MNDR | hsa-miR-152-3p | Head and neck cancer | MNDR-E-MI-17018 |
| MNDR | hsa-miR-152-3p | Dengue disease | MNDR-E-MI-17019 |
| MNDR | hsa-miR-152-3p | Cardiovascular disease | MNDR-E-MI-17020 |
| MNDR | hsa-miR-152-3p | Carotid stenosis | MNDR-E-MI-17021 |
| MNDR | hsa-miR-152-3p | Brain cancer | MNDR-E-MI-17022 |
| MNDR | hsa-miR-152-3p | Lung cancer | MNDR-E-MI-17023 |
| MNDR | hsa-miR-152-3p | Endometrial cancer | MNDR-E-MI-17024 |
| MNDR | hsa-miR-152-3p | Parkinson disease | MNDR-E-MI-17025 |
| MNDR | hsa-miR-152-3p | Niemann-pick disease | MNDR-E-MI-17026 |
| MNDR | hsa-miR-152-3p | Breast cancer | MNDR-E-MI-17027 |
| MNDR | hsa-miR-152-3p | Thyroid cancer | MNDR-E-MI-17028 |
| MNDR | hsa-miR-152-3p | Pancreatic cancer | MNDR-E-MI-17029 |
| MNDR | hsa-miR-152-3p | Malignant melanoma | MNDR-E-MI-17030 |
| MNDR | hsa-miR-152-3p | Gaucher disease | MNDR-E-MI-17031 |
| MNDR | hsa-miR-152-3p | Rectum adenocarcinoma | MNDR-E-MI-17032 |
| MNDR | hsa-miR-152-3p | Nephroblastoma | MNDR-E-MI-17033 |
| MNDR | hsa-miR-152-3p | Colon cancer | MNDR-E-MI-17034 |
| MNDR | hsa-miR-152-3p | Colon adenocarcinoma | MNDR-E-MI-17035 |
| MNDR | hsa-miR-152-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-17036 |
| MNDR | hsa-miR-152-3p | Familial ovarian cancer | MNDR-E-MI-17037 |
| MNDR | hsa-miR-152-3p | Prostate adenocarcinoma | MNDR-E-MI-17038 |
| MNDR | hsa-miR-152-3p | Hematologic cancer | MNDR-E-MI-17039 |
| MNDR | hsa-miR-152-3p | Carcinoma ductal breast | MNDR-E-MI-17040 |
| MNDR | hsa-miR-152-3p | Glioblastoma | MNDR-E-MI-17041 |
| MNDR | hsa-miR-152-3p | Glioma | MNDR-E-MI-17042 |
| MNDR | hsa-miR-152-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-17043 |
| MNDR | hsa-miR-152-3p | Meningioma | MNDR-E-MI-17044 |
| MNDR | hsa-miR-152-3p | Liver neoplasms | MNDR-E-MI-17045 |
| MNDR | hsa-miR-152-3p | Cervical adenocarcinoma | MNDR-E-MI-17046 |
| MNDR | hsa-miR-152-3p | Gastric adenocarcinoma | MNDR-E-MI-17047 |
| MNDR | hsa-miR-152-3p | Lung carcinoma | MNDR-E-MI-17048 |
| MNDR | hsa-miR-152-3p | Lung squamous cell carcinoma | MNDR-E-MI-17049 |
| MNDR | hsa-miR-152-3p | Non-small cell lung adenocarcinoma | MNDR-E-MI-17050 |
| MNDR | hsa-miR-152-3p | Lung adenocarcinoma | MNDR-E-MI-17051 |
| MNDR | hsa-miR-152-3p | Thyroid carcinoma | MNDR-E-MI-17052 |
| MNDR | hsa-miR-152-3p | Ovarian carcinoma | MNDR-E-MI-17053 |
| MNDR | hsa-miR-152-3p | Bladder urothelial carcinoma | MNDR-E-MI-17054 |
| MNDR | hsa-miR-152-3p | Pancreatic adenocarcinoma | MNDR-E-MI-17055 |
| MNDR | hsa-miR-152-3p | Carcinoma renal cell | MNDR-E-MI-17056 |
| MNDR | hsa-miR-152-3p | Renal clear cell carcinoma | MNDR-E-MI-17057 |
| MNDR | hsa-miR-152-3p | Cholangiocarcinoma | MNDR-E-MI-17058 |
| MNDR | hsa-miR-152-3p | Esophageal cancer | MNDR-E-MI-17059 |
| MNDR | hsa-miR-152-3p | Liver cirrhosis | MNDR-E-MI-17060 |
| MNDR | hsa-miR-152-3p | Lung small cell carcinoma | MNDR-E-MI-17061 |
| MNDR | hsa-miR-152-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-17062 |
| MNDR | hsa-miR-152-3p | Breast invasive carcinoma | MNDR-E-MI-17063 |
| MNDR | hsa-miR-152-3p | Early hepatocellular carcinoma | MNDR-E-MI-17064 |
| MNDR | hsa-miR-152-3p | Familiar ovarian carcinoma | MNDR-E-MI-17065 |
| MNDR | hsa-miR-152-3p | B-cell lymphoma | MNDR-E-MI-17066 |
| MNDR | hsa-miR-152-3p | Rheumatoid arthritis | MNDR-E-MI-17067 |
| MNDR | hsa-miR-152-3p | Neuroblastoma | MNDR-E-MI-17068 |
| MNDR | hsa-miR-152-3p | Chronic fatigue syndrome | MNDR-E-MI-17069 |
| MNDR | hsa-miR-152-3p | Hodgkin lymphoma | MNDR-E-MI-17070 |
| MNDR | hsa-miR-152-3p | Neuromyelitis optica | MNDR-E-MI-17071 |
| MNDR | hsa-miR-152-3p | Acute myeloid leukemia | MNDR-E-MI-17072 |
| MNDR | hsa-miR-152-3p | Colorectal cancer | MNDR-E-MI-17073 |
| MNDR | hsa-miR-152-3p | Nasopharynx carcinoma | MNDR-E-MI-17074 |
| MNDR | hsa-miR-152-3p | Type 2 diabetes mellitus | MNDR-E-MI-17075 |
| MNDR | hsa-miR-152-3p | Acute lymphocytic leukemia | MNDR-E-MI-17076 |
| MNDR | hsa-miR-152-3p | Ovarian epithelial cancer | MNDR-E-MI-17077 |
| MNDR | hsa-miR-152-3p | Nasopharyngeal cancer | MNDR-E-MI-17078 |
| MNDR | hsa-miR-152-3p | Prostatic neoplasms | MNDR-E-MI-17079 |
| MNDR | hsa-miR-152-3p | Epstein-barr virus infections | MNDR-E-MI-17080 |
| MNDR | hsa-miR-152-3p | Cerebral hemorrhage traumatic | MNDR-E-MI-17081 |
| MNDR | hsa-miR-152-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-17082 |
| MNDR | hsa-miR-152-3p | Stroke lacunar | MNDR-E-MI-17083 |
| MNDR | hsa-miR-152-3p | Breast cancer her3+ negative | MNDR-E-MI-17084 |
| MNDR | hsa-miR-152-3p | High grade dysplastic nodule | MNDR-E-MI-17085 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ADAM17 | Homo sapiens | RR00040511 |
TOP